Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 4/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.52 |
| ▸ | NPY1R | P25929 | 3/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 6/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14351275 | 1.00 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RNOD1 | |
| SCHEMBL2150776 | 0.99 | NPY4R (0.51) | NPY4RNPY5RNPY1RNPY2RNOD1 | |
| SCHEMBL3651453 | 0.94 | NOD1 (0.55) | NPY4RNPY5RNPY1RNPY2RNOD1 | |
| SCHEMBL17304345 | 0.94 | NOD1 (0.52) | NPY4RNPY5RNPY1RNPY2RNOD1 | |
| SCHEMBL17304352 | 0.94 | NOD1 (0.52) | NPY4RNPY5RNPY1RNPY2RNOD1 | |
| SCHEMBL17304354 | 0.94 | NOD1 (0.52) | NPY4RNPY5RNPY1RNPY2RNOD1 | |
| SCHEMBL17304348 | 0.94 | NOD1 (0.52) | NPY4RNPY5RNPY1RNPY2RNOD1 | |
| SCHEMBL17304349 | 0.94 | NOD1 (0.52) | NPY4RNPY5RNPY1RNPY2RNOD1 | |
| SCHEMBL17304347 | 0.94 | NOD1 (0.52) | NPY4RNPY5RNPY1RNPY2RNOD1 | |
| SCHEMBL17304342 | 0.94 | NOD1 (0.52) | NPY4RNPY5RNPY1RNPY2RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222269-A1 | IMPROVED DERIVATIVES OF AMYLIN | NOVO NORDISK A/S (DK) | 2010-09-02 | — | — | US | disclosed |
| EP-2190871-A1 | IMPROVED DERIVATIVES OF AMYLIN | Novo Nordisk A/S (DK) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009034119-A1 | IMPROVED DERIVATIVES OF AMYLIN | NOVO NORDISK A/S (DK) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222269-A1 | IMPROVED DERIVATIVES OF AMYLIN | IAPP, GLP1R, ALB | NPY4R 190/4885NPY5R 223/4885NPY1R 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.